MetaCap

BridgeBio Pharma (BBIO) vs TG Therapeutics (TGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TG Therapeutics (TGTX) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 98.2% versus a gain of 11.6%. Over five years, TGTX leads with a +164.1% price change compared with +92.2% for BBIO. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $9.57 billion), about 1.5 times the size.

TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%TGTX+98.25%
+113%+46%-22%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%TGTX+159.48%
+177%+40%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus TGTX key metrics
MetricBBIOTGTX
Share price$76.03$63.34
Market cap$14.81B$9.57B
1-day change-2.75%-2.37%
YTD return-0.60%+112.48%
1-year return+11.63%+98.25%
5-year return+92.24%+164.14%
P/E ratio (TTM)—94.54
Forward P/E—24.81
EPS (TTM)$-3.03$0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$502.08M$616.29M
Revenue growth (YoY)+126.26%+87.32%
Net income (latest FY)$-732.94M$447.18M
Gross margin95.82%83.66%
Operating margin-104.25%20.01%
Net margin-145.98%72.56%
52-week high$93.42$68.03
52-week low$62.50$26.76
Distance from 52-week high-18.61%-6.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+40.73%+9.61%
Average volume2.67M1.86M
Shares outstanding194.80M151.15M
Employees1,081399
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TGTX has outperformed BBIO by 86.6 percentage points over the past year.
  • TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +87.32%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About TG Therapeutics

TGTX stock →

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees

BBIO vs TGTX FAQ

Which is bigger, BridgeBio Pharma or TG Therapeutics?

BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $9.57B for TG Therapeutics (TGTX).

Which stock has performed better over the past year, BBIO or TGTX?

TGTX returned +98.25% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Pharma and TG Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons